Clinical Trial

LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-04-27; most recent amendment 2026-07-21.
Status change: Not Yet Recruiting → Recruiting 2025-08-21
Trial Details
NCT Number NCT06958107
Lead Sponsor Wake Forest University Health Sciences
Collaborators: Paula Takacs Foundation
Conditions Sarcoma
Enrollment 300 participants
Start Date 2025-08-21
Primary Completion 2030-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-23